Could a vibrating platform help people with stiff lungs breathe easier?
NCT ID NCT07709260
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether adding whole-body vibration to standard pulmonary rehabilitation can improve lung function, exercise capacity, and quality of life in adults aged 40–80 with fibrotic interstitial lung disease. Participants are randomly assigned to either rehab alone or rehab plus vibration sessions twice a week for 8 weeks. The goal is to see if the vibration platform provides extra benefits for breathing and daily function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- whole-body vibration training added to standard pulmonary rehabilitation
- What this could lead to
- If it works, this could offer a simple, drug-free way to boost exercise capacity and ease breathlessness in people with fibrotic lung disease.
- What could go wrong
- This is a small, early-stage trial with only 26 participants, so results may not apply widely. The vibration may cause discomfort or fail to provide extra benefit over standard rehab alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi
Üsküdar, Istanbul, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive study tracks lung disease progression in 4,000 patients
- New pill aims to halt lung scarring in thousands
- Massive 10-Year study aims to unlock secrets of rare lung disease
- Could a cancer drug slow lung scarring? new trial tests anlotinib for IPF
- Lung cancer and scarred lungs: a dangerous duo under the microscope
- 7,000 patients join tissue bank to unlock secrets of lung disease